Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

François-Xavier Bagnoud Professor of Pediatrics
Department of Pediatrics
University of Medicine and Dentistry of New Jersey
New Jersey Medical School
Newark, NJ

Topics of Professional Interest:
  • Pediatric HIV management/long-term follow-up
  • Pediatric care, quality of life
  • Pediatric antiretroviral treatment guidelines
  • Pediatric palliative care and pain management in children with chronic illnesses
  • Prevention, treatment of perinatal HIV infection
Current Professional Summary:

Dr Oleske is the François-Xavier Bagnoud Professor of Pediatrics, and Director of the Division of Pulmonary, Allergy, Immunology & Infectious Diseases at the New Jersey Medical School. He is also the Medical Director for the Center for Laboratory Investigations at the New Jersey Medical School and an attending at the University Hospital in Newark, NJ.

Committees and Organizations:
  • Member, American Academy of Pediatrics
  • Member, American Academy of HIV Medicine
  • Member, Infectious Disease Society of America
  • Chair, US Pediatric Antiretroviral Treatment Guidelines
  • Chair Emeritus, PACTG Protocol 219C Long-Term Follow-Up
Honors and Awards:
  • François-Xavier Bagnoud Professor of Pediatrics, UMDNJ/NJMS — Endowed Chair (1990)
  • 10 Best Pediatricians in America (1992)
  • John P. Johnson Lectureship Award, University of Maryland (1997)
  • Heroes in Medicine Award, IAPAC, Toronto, Canada (2000)
  • 2001 Arnold P. Gold Humanitarian Award, The Healthcare Foundation of New Jersey (2001)
  • College of Medicine and Dentistry of New Jersey, MD in Medicine (1971)
  • College of Medicine and Dentistry of New Jersey, Residency in Pediatrics (1971-1973)
  • Grady Memorial Hospital, Fellow in Pediatric Infectious Disease and Immunology (1974-1976)
Selected Publications:
  1. Oleske J, Minnefor A, Cooper R, et al. Immune deficiency syndrome in children. JAMA. 1986;249:2345-2349.
  2. Oleske J, Czarniecki L. Continuum of palliative care: lessons from caring for children infected with HIV-1. Lancet. 1999;354:1287-1291.
  3. Hanson I, Antonelli T, Sperling R, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. JAIDS. 1999;20:463-467.
  4. Culname M, Fowler M, Lee S, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA. 1999;281:151-157.
  5. Gortmaker S, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Eng J Med. 2001;345:1522-1528.
  6. Buchacz K, Cervia J, Lindsey J, et al. Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatrics. 2001;108:E72.
  7. Gaughan D, Mofenson L, Hughes M, et al. Osteonecrosis of the hip (Legg-Calve-Perthes Disease) in human immunodeficiency virus-infected children. Pediatrics. 2002;100:E74.
  8. Gaughan D, Hughes M, Seage G, et al. The prevalence of pain in pediatric HIV/acquired immunodeficiency syndrome as reported by participation in the pediatric late outcomes study (PACTG 219). Pediatrics. 2002;109:1144-1152.
  9. Soh C, Oleske J, Brady M, et al. Long-term effects of protease-inhibitor based combination therapy on CD4 T-cell recovery in HIV-1 infected children and adolescents. Lancet. 2003;362:2045-2051.
  10. Gaughan D, Hughes M, Oleske J, et al. Psychiatric hospitalization among children and youths with HIV infection. Pediatrics. 2004;113:e544-e551.